Celyad Oncology SA CYAD-BE:Euronext Brussels

RT Quote | Exchange | EUR
Last | 01/27/23 CET
1.15UNCH (UNCH)
52 week range
0.50 - 3.40
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close1.15
  • 52 Week High3.40
  • 52 Week High Date01/24/22
  • 52 Week Low0.50
  • 52 Week Low Date12/27/22

Key Stats

  • Market Cap28.28M
  • Shares Out22.59M
  • 10 Day Average Volume379,261.75
  • Dividend-
  • Dividend Yield-
  • Beta1.13
  • YTD % Change128.06

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close1.15
  • 52 Week High3.40
  • 52 Week High Date01/24/22
  • 52 Week Low0.50
  • 52 Week Low Date12/27/22
  • Market Cap28.28M
  • Shares Out22.59M
  • 10 Day Average Volume379,261.75
  • Dividend-
  • Dividend Yield-
  • Beta1.13
  • YTD % Change128.06

RATIOS/PROFITABILITY

  • EPS (TTM)-1.30
  • P/E (TTM)-0.89
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Celyad Oncology SA

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Celyad Oncology SA, formerly Celyad SA is a Belgium-based company. The Company is a clinical-stage biotechnology company focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company develops allogeneic and autologous CAR T cell therapy candidates for cancer patients with hematological malignancies and solid tumors. The Company's product, CYAD-101 is a NKG2D receptor-based CAR T, which incorporates non-gene edited...
Hilde Windels
Chairwoman of the Board
Michel Lussier
Interim Chief Executive Officer, Director
Fredrik Lehmann Ph.D.
Vice President Clinical Development and Medical Affairs - Representative of ImXense SRL, Member of the Executive Management Committee
Address
Axis Business Park Rue Edouard Belin 2
Mont-saint-guibert
1435
Belgium